Compare ABUS & ALOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABUS | ALOY |
|---|---|---|
| Founded | 2005 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.0M | 862.3M |
| IPO Year | 2008 | 2021 |
| Metric | ABUS | ALOY |
|---|---|---|
| Price | $4.35 | $7.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 6.3M | 1.7M |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $14,083,000.00 | $692,803.00 |
| Revenue This Year | $1,208.75 | $258.37 |
| Revenue Next Year | N/A | $926.02 |
| P/E Ratio | $4.98 | ★ N/A |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.50 | $5.91 |
| 52 Week High | $5.45 | $26.90 |
| Indicator | ABUS | ALOY |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 36.97 |
| Support Level | $4.17 | $6.83 |
| Resistance Level | $4.57 | $9.42 |
| Average True Range (ATR) | 0.18 | 0.42 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 15.43 | 37.24 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
REalloys Inc is a development-stage company building a North American integrated rare earth to high-performance neodymium iron boron (NdFeB) magnet materials and magnet supply chain focused on meeting the demands of the protected markets of the United States, which includes the U.S. National Defense Stockpiles (NDS), Defense Industrial Base (DIB), Nuclear Industrial Base (NIB), robotics, electric aviation, and critical infrastructure industries. The company operates in a single, integrated rare-earth development and supply chain enterprise focused on building a North American mine-to-magnet supply chain for U.S. Protected Markets.